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ABSTRACT 
Nystatin containing microsponge as active constituent (API) in different formulations by changing the proportions of drug (Nystatin), polymer 
(ethyl cellulose), emulsifier (Poly vinyl alcohol) were obtained successfully using quasi-emulsion solvent diffusion method. These formulations 
were studied for particle size and physical characterization. Scanning electron microscopy (SEM) images showed the microspong es porous and 
spherical in shape. The physical characterization showed that microsponge formulation coded by P6 showed a better loading efficiency and 
production yield. This microsponge formulation was prepared as gel in carbopol and studied for pH, viscosity, spreadability, drug content, in-
vitro release. The microsponge formulation gel, F3 showed viscosity3465.84cps, spreadability of 26.22g cm/s and drug content of 89.65%. The 
nystatin microsponge gel formulations showed an appropriate drug release profile. F3 released 81.03% of drug at 12 hours.  
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INTRODUCTION 
A microsponge delivery system (MDS) is, highly cross-linked, 
porous, polymeric system consisting of porous microspheres 
that can entrap wide range of actives and then release them 
over a time and in response to trigger.1,2,3 Moreover, they 
may enhance stability, reduce side effect and modify 
drugrelease favorably. Microsponges are polymeric delivery 
systems composed of porous microspheres of an inert 
polymer that can entrap active ingredients and control their 
delivery rate. The size of these microsponges can be varied, 
usually from 5 to 300μm in diameter depending on the 
degree of smoothness1. However by optimizing formulation 
parameters such as drug: polymer ratio and agitation/ 
stirring rate it might be possible to manufacture 
microsponge.4 
The microsponges behave like a reservoir of the active 
ingredients. These can potentially be used for the controlled 
delivery of a large variety of substances such as fragrances, 
emollients, sunscreens, anti-inflammatory, antifungal, 
antimicrobial agents A microsponge system offers the 
potential to hold active ingredients in a protected 
environment and provide controlled delivery onto the skin 
over a time as well as oral medication to the lower 
gastrointestinal (GI) tract, where it will be released upon 
exposure to specific enzymes in the colon.5-8 
Nystatin is a polyene antifungal characterized by a potent 
broad-spectrum antifungal action including a wide range of 
pathogenic and non-pathogenic yeasts and fungi. The 
Nystatin is active against a variety of fungal pathogens 
including: Candida, Aspergillus, Nystatin exerts its antifungal 
activity by binding to sterols in the fungal cell membrane. 
When present in sufficient concentrations, it forms pores in 
the membrane that lead to K+ leakage, acidification, and 
death of the fungus.9-13  
MATERIAL AND METHODS 
Nystatin is a gift sample from Glenmark Pharmaceuticals 
Ltd.Carbapol 974P, HPMC K4, Propylene glycol, Triethano 
lamine. From Research-Lab Fine Chem, Mumbai 
Method of Preparation: 
Formulation of Nystatin loaded Microsponge 
 Microsponge was prepared by quasi-emulsion 
solvent diffusion method. 
Ethyl cellulose based Nystatin loaded microsponge was 
prepared by quasi-emulsion solvent diffusion method. The 
internal phase consisted of ethyl cellulose (1 gm) and 
dissolved in 20 ml dichloromethane. The drug was added to 
this with gradual stirring (500 rpm). The internal phase was 
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then poured into 0.5 % w/v polyvinyl alcohol (PVA, 
molecular weight 30,000-70,000) solution in water, the 
external phase. After 8 hour of stirring the microsponges 
were formed due to removal of dichloromethane from the 
system. The microsponges were filtered and dried at 40°C for 
12 hours.2, 14-19 
 
 
 Preliminary studies 
Table no 1: Preliminary studies on formulation of Microsponge: 
Sr 
No. 
 
Ingredient 
Quantity in % (w/v) 
P1 P2 P3 P4 P5 P6 P7 P8 
1 Nystatin(gm) 1 1.5 2 2.5 3 3.5 4 4.5 
2 Ethyl cellulose(gm) 1 1 1 1 1 1 1 1 
3 Polyvinyl alcohol (mg) 50 50 50 50 50 50 50 50 
4 Dichloromethane(ml) 10 10 10 10 10 10 10 10 
5 Distilled water 200 200 200 200 200 200 200 200 
 
Preliminary studies for formulation of microsponge were 
carried out as follows.  ethyl cellulose was selected as a 
polymer and used for the sustained release mechanism for 
preparation of microsponge. DMSO is used as solvent and 
polyvinyl alcohol is used as cross linking agent. Preliminary 
studies on formulation of microsponges were carried out by 
taking various concentrations shown 
Evaluation of drug loaded microsponge:20-31 
The prepared microsponges were evaluated for the following 
parameter: 
 Drug content: 
 Entrapment efficiency: 
 Partical size and size distribution analysis: 
 Angle of repose 
 Determination of Density: 
i. Bulk Density     
ii. Tapped Density: 
 Compressibility index :( Carr’s Index) 
 Hausners ratio 
7.6.7. In-Vitro Drug Release Studies 
In-vitro Dissolution Studies: 
Nystatin (Pure Drug) & Nystatin loaded Microsponges were 
subjected to dissolution test using in-vitro dissolution rate 
USP Apparatus-II. (Paddle method). This test was performed 
using 900 ml of dissolution medium buffer solution PH 6.8 at 
37±2ºC. Accurately weighed samples (plain drug and 
Nystatin loaded microsponges) approx. 20mg of drug were 
added in 900 ml capacity jar of dissolution apparatus which 
paddle was rotated at 50 rpm. A 5ml aliquot of dissolution 
medium was withdrawn at appropriate time intervals. An 
equal volume of fresh dissolution medium was immediately 
replaced. It was suitably diluted and analyzed 
spectrophotometrically by measuring absorbance at 305nm. 
The experiments were performed in triplicate.  
X-ray powder diffraction (XRD): 
To understand XRD pattern of pure drug and optimized 
formulation, a Philips 1710 X-ray Defractometer (XRD) with 
a copper target and nickel filter was used to obtain XRD 
result for the samples. Powder were mounted on aluminium 
stages with glass bottoms and smoothed to a level surface. 
The XRD pattern of each sample was measured from 10- 500 
(2θ) using a step increment of 0.10 (2θ) and a dwell time of 1 
second at each step. 
Differential scanning calorimetry (DSC): 
Thermogram of Nystatin, and Drug: SSG formulations were 
recorded by using “Miller Star sw 9.01” differential scanning 
calorimeter. Thermal behaviour of the samples was 
investigated under a scanning rate of 10ºC/ min, covering a 
temperaturerange of 100- 300ºC. The heat flow as a function 
of temperature was measured for both the drug and 
Microsponge. 
Preparation of a Nystatin gel: 
Nystatin, an antifungal drug was selected as a drug model in 
this study. The drug concentration in all formulations was 
kept constant at 1.72% w/w. and the concentration of 
dimethyl sulphoxide was also kept constant at 5% w/w. 
dimethyl sulphoxide was used as co-solvent and as a 
dispersion medium for the nystatin. Four formulations like 
F1,F2,F3,F4 containing 0.5, 1, 1.5, 2 %w/w(Raymond Rowe)  
polymer (carbopol ) Triethanolamine was used to neutralize 
and adjust the pH of the gel systems. 
Carbopol was accurately weighed and dissolved in half 
quantity of distilled water and left for 2 hrs to swell and form 
gel. Solvent blend of dimethyl sulphoxide which contain 
microsponges equivalent to 1.72%w/w Nystatin with 
constant stirring. To the whole mixture added 
triethanolamine dropwise until transparent gel was 
obtained. Stirring was stopped to escape entrapped 
air;further formed gel was stored in air tight container for 
further study. 
Table 2: Preparation of a Nystatin gel 
Ingredient Nystatin gel Microsponge loaded Batch 
F1 F2 F3 F4 
Nystatin   1.72gm 1.90gm 1.90gm 1.90gm 1.90gm 
Carbapol(%w/w) 1.5 0.5 1 1.5 2 
DMSO(%w/w) 5 5 5 5 5 
Triethanolamine(ml) 1 1 1 1 1 
Distilled water q.s. q.s. q.s. q.s. q.s. 
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7.11. Physicochemical evaluations 
7.11. 1. Physical appearance:- 
The prepared Nystatin formulations containing Nystatin 
were inspected visually for their colour, homogeneity, 
consistency and phase separation. 
7.11. 2. Measurement of pH:- 
The pH of developed Nystatin formulations was determined 
using digital pH meter 
7.11.3. Spreadability:- 
Spreading coefficient was determined by apparatus 
suggested by Lalit Kumar et.al.,2010. It consists of a wooden 
block, which is attached to a pulley at one end. Spreading 
coefficient was measured on the basis of ‘Slip’ and ‘Drag’ 
characteristics of Nystatins. Spreadabilityis calculated by 
using the formula. 
S = M. L / T 
Where, M = wt. tied to upper slide 
L = length of glass slides,   T = time taken to separate the 
slides 
Rheological Study: 
The viscosity of the developed Nystatin formulations was 
determined by using a Brookfield viscometer  
Drug Content Determination:  
Nystatin was measured by dissolving known quantity of 
Nystatin in solvent (DMSO) by Sonication. Absorbance was 
measured after suitable dilution at 305 nm using UV 
spectrophotometer.  
7.11.6. In Vitro Diffusion Studies: 
The in vitro drug release studies were carried out using a 
modified Franz diffusion cell.   The formulation was applied 
on rat skin (which was previously soaked in Phosphate 
buffer pH 6.8 for 24 hours) which was sandwiched between 
donor and receptor compartment of the Franz diffusion cell. 
Phosphate buffer pH 6.8 was used as a dissolution media. 
The temperature of the cell was maintained at   34±0.2 0C by 
kept it in water bath. This whole assembly was kept on a 
magnetic stirrer and the solution was stirred continuously 
using a magnetic bead at 50 rpm. The samples were 
withdrawn at suitable time interval and analysed for drug 
content by UV visible spectrophotometer at 305 nm after 
appropriate dilutions.  
RESULT 
Evaluation of Nystatin microsponge: 
During Preliminary studies for the formulation of Nystatin 
microsponge, different parameters were studied in different 
range like, drug to polymer ratio, stirring speed, stirring 
time, internal volume, and surfactant concentration. 
8.4: Evaluation of optimized microsponge:32-40 
8.4.1: Scanning electron microscopy: 
Morphology of microsponges was examined by scanning 
electron microscopy. As it can be seen from the SEM images 
(Figure.8.6) the microsponge presented a rough surface with 
characteristic large wrinkles and micropores. microsponge 
were spherical shape and showed sponge like structure 
where the drug was entrapped. 
 
                           (a) (b) 
 
Figure 8.6 (a) Scanning electron microphotographs of   final formulation. 
(b) surface morphology of optimize batch 
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8.4.2. FTIR Spectroscopy:- 
FTIR Spectra of Surface solid dispersion of Nystatin in comparison with pure drug was done to determine the interaction 
between drug and polymer. Result of FTIR graph is shown in following figure. 
 
 
Nystatin 
 
Nystatin microsponge 
Figure 8.7: Comparative FTIR Spectra of Nystatin &microsponge 
 
From the FTIR spectrum of the microsponge of Nystatin in 
Comparison with Pure drug (Nystatin) it was concluded that 
there was no any Change in the position of peak of 
microsponge. So there is no any Interaction between drug 
and polymer used in the Microsponge formulation. 
8.4.3: Diffrential scanning calorimetry: 
Differential Scanning Calorimetry (DSC) study was carried 
out for Microsponge Of Nystatin. The obtained result is 
shown in Fig.No.8.8. DSC Studies indicate the endothermic 
peak at 160°C which of the melting point of Nystatin drug. 
There was no any major change in the position of peak in 
Comparison with pure drug (Nystatin). The decrease in the 
sharpness of the peak in the Microsponge was the indication 
of drug convert from crystalline to Disorder crystalline or 
amorphous form & which was confirm by the XRD study. 
There was no change in melting point is indication of the 
drug is in the stable form in the microsponge formulation. 
 
 
Figure 8.8: Comparative DSC graph of Microsponge of Nystatin 
 
8.4.4 X-ray diffractometry: 
Powder X ray diffraction analysis was carrie;d out for 
Microsponge of Nystatin. Powder X ray diffraction study 
indicates the number of peaks and peak height was reduced 
in microsponge which was the indication of change in crystal 
habits. There was also change in Diffraction angle (2θ) value 
indicate change in crystal lattice of Nystatin. These findings 
suggest that the Nystatin crystals get converted to disorder 
crystalline form or amorphous form in surface solid 
dispersion. XRD graph of microsponge of Nystatin is shown 
in fig. No.8.9. 
nystati n Name Description 
4000 450 3500 3000 2500 2000 1500 1000 500 
 
 
121 
9 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
cm-1 
%T 
1069.22cm- 1, 11.36%T 1008.39cm- 1, 15.07%T 3367.56cm- 1, 20.99%T 1399.33cm- 1, 24.81%T 2931.30cm- 1, 25.17%T 1185.31cm- 1, 26.95%T 1575.80cm- 1, 27.53%T 
1448.18cm- 1, 30.14%T 1322.55cm- 1, 33.94%T 1702.36cm- 1, 34.72%T 
1282.70cm- 1, 40.44%T 1261.70cm- 1, 43.48%T 3012.85cm- 1, 43.59%T 846.36cm-1, 44.02%T 527.48cm-1, 49.06%T 
916.19cm-1, 56.78%T 
884.79cm-1, 56.78%T 
903.50cm-1, 57.15%T 
795.05cm-1, 61.35%T 
692.39cm-1, 61.92%T 
737.32cm-1, 62.07%T 
710.00cm-1, 62.32%T 
nystati n microspong e Name Description 
4000 450 3500 3000 2500 2000 1500 1000 500 
81 
23 25 
30 35 
40 45 
50 55 
60 65 
70 
75 
cm-1 
%T 
1111. 23c m-1,  24. 58%T 1055.03cm- 1, 24.89%T 
2974. 78c m-1,  25. 03%T 
2872. 50c m-1,  26. 90%T 
2930. 09c m-1,  27. 74%T 
3479. 88c m-1,  30. 35%T 1376. 92c m-1,  34. 62%T 
1355. 22c m-1,  39. 50%T 1445. 01c m-1,  41. 80%T 
1311.21cm- 1, 42.14%T 
1281. 20c m-1,  43. 42%T 
1731. 84c m-1,  49. 19%T 
919.8 1cm -1, 55.0 2%T 882.8 1cm -1, 57.8 4%T 
576.9 7cm -1, 65.7 5%T 
Bansode et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):451-461 
ISSN: 2250-1177                                                                                  [455]                                                                                 CODEN (USA): JDDTAO 
 
 
Figure 8.9: XRD of Nystatin and Nystatin microsponge. 
 
8.4.4:  In Vitro Drug release through microsponge: 
The drug release of Nystatin microsponges were carried out 
into in USP type II apparatus. Using buffer solution PH 6.8 a 
dissolution medium having capacity of 900ml. dissolution 
was carried out up to 12 hours. The drug release was found 
to be 92.11% at 17th hour. The microsponge shows 
sustained drug release. 
 
Figure 8.9: % drug release through microsponges 
8.5. RESULTS AND DISCUSSION 
Solubility study, loss on drying, angle of repose and melting 
point determination of nystatin and nystatin microsponge 
was done. Nystatin is soluble in DMSO and Melting point was 
found tobe 160- 1660C. The literature value is 1600C 
 
Table 8.9: LOD of Nystatin and Nystatin microsponge 
Material LOD % 
Nystatin 0.32% 
Nystatin microsponge 0.33% 
 
Table 8.10: Angle of Repose of Nystatin & Nystatin 
microsponge 
Material Observation 
Nystatin 290.30” 
Nystatin Microsponge 310.82” 
 
8.5.5. Spectroscopic studies:- 
(a) UV Spectroscopy:- 
After studying the UV- spectra Nystatin, it was found that it 
shows maximum absorbance at 305 nm.  
 
 
Figure 8.10: λmax for Nystatin 
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(b) DSC Thermogram:- 
The DSC thermogram of Nystatin Microsponge was recorded using Differential Scanning Calorimeter. The DSC thermogram 
shows melting endothermic at160 °C. 
 
Figure 8.11: DSC Thermo gram of Nystatin 
8.5.6. Calibration Curve: 
λmax value for Nystatin Microsponge was found to be 305 nm from UV spectra. The solvent used for the preparation of 
calibration curve for Nystatin Microsponge are phosphate buffer pH 6.8solution. The regression coefficient value was found to 
be 0.996. 
 
Figure 8.12: Calibration of Nystatin Microsponge
8.5.7. Compatibility Studies:  
After 30 days of drug with excipient in various ratio storage at room temperature, samples were observed for physical changes 
but there were no physical changes observed in the mixture of Nystatin Microsponge and polymer combination. 
Compatibility Studies BY FTIR 
 
Figure 8.13(A): FTIR of Nystatin 
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Figure 8.13(B):FTIR of Nystatin microsponge 
 
Figure 8.13(C): FTIR of Nystatin microsponge + Carbapol 
A- Nystatin. 
Table 8.13: Functional group of FTIR 
 
 
8.5.8. Differential Scanning Calorimetriy (DSC) 
The DSC analysis of pure drug, polymer and mixture were carried using DSC to evaluate any possible drug polymer interaction. 
All the prominent thermograms of the drug and polymer were retained. Thus, no interactions were observed between the drug 
and excipients. Hence drug excipients compatibility was established shows DSC of drug, polymer and drug-polymer mixture. 
 
Figure 8.14: DSC Thermogram of Nystatin 
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Figure 8.15:   DSC Thermogram of Mixture Nystatin +Nystatin Microsponge 
8.5.10. Formulation table 
Table 8.14: Formulation table for Nystatin gel & Nystatin Microsponge Gel. 
Ingredient Nystatin gel Microsponge loaded Batch 
F1 F2 F3 F4 
Nystatin   1.72gm 1.90gm 1.90gm 1.90gm 1.90gm 
Carbapol (%w/w) 1.5 0.5 1 1.5 2 
DMSO (%w/w) 5 5 5 5 5 
Triethanolamine (ml) 1 1 1 1 1 
Distilled water q.s. q.s. q.s. q.s. q.s. 
 
8.6. Physicochemical evaluation: 
8.6.1. Physical appearance:- 
The prepared Nystatin micropsonge gel formulations were A gel is a solid, jelly-like material that can have properties ranging 
from soft and weak to hard and tough. Gels are defined as a substantially dilute cross-linked system, which exhibits no flow 
when in the steady-state. All gel found to be transparent. 
8.6.2. Measurement of pH:- 
The pH values of all prepared formulation ranged from which are. 
Table 8.15: pH of Nystatin &Nystatinmicropsonge gel formulation 
 
 
 
8.6.3. Spreadability:- 
The spreadability of various gel formulations is depicted in graph it was concluded that all the developed formulation showed 
acceptable spreadability 
Table 8.16: Spreadability of Nystatin formulation 
Batch Nystatin gel F1 F2 F3 F4 
Spreadability (gm.cm/sec.) 19.60 22.66 16.66 26.22 19.06 
 
 
Figure 8.16: spreadability of Nystatin micropsonge gel formulation 
Batch Nystatin gel F1 F2 F3 F4 
Ph 6.8 6.9 6.4 6.9 6.8 
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8.6.4. Rheological Study:- 
The measurement of viscosity of the prepared Nystatin was done with Brookfield viscometer. The highest viscosity was found 
in formulation it may be due to low level of the liquid paraffin concentration and emulsifying agent concentration. The lowest 
viscosity was found in formulation f1. 
Table 8.16: Viscosity of Nystatin microsponge gel formulation 
Batch Nystatin gel F1 F2 F3 F4 
Viscosity(cps) Speed 12 rpm 3020.20 3409.93 2962.73 3465.84 2180.12 
 
 
Figure 8.17: Viscosity of gel formulation 
8.6.5. Drug Content Determination:- 
Drug content was calculated using the equation, which was obtained by linear regression analysis of calibration curve. The drug 
content of all gel formulation is given in table.                  Y = 0.024x - 0.004     R² = 0.996. 
Table 8.17: Drug content of Nystatin micropsonge gel formulation 
Batch Nystatin gel F1 F2 F3 F4 
Drug content (%) 65.18 87.56 84.93 89.65 86.93 
 
 
Figure 8.18: Drug content of Nystatin micropsonge gel formulation 
8.7. In Vitro Diffusion Studies 
The in vitro release profiles of Nystatin micropsonge from its various gel formulations 
Table 8.18:   In-vitro diffusion studies 
Time(hrs) 
Nystatin gel Microsponge loaded batches 
F1 F2 F3 F4 
0.5 2.125 3.258 2.855 4.528 3.569 
1 2.577 4.256 5.365 6.568 4.365 
2 5.155 8.547 8.355 8.927 7.934 
3 7.572 11.948 11.672 12.670 11.103 
4 11.913 21.532 20.913 21.128 20.326 
5 14.617 26.142 27.217 28.312 27.531 
6 19.226 31.943 32.526 33.982 32.945 
7 25.129 39.462 40.129 42.783 40.186 
8 32.178 46.932 48.978 49.821 47.544 
9 38.692 55.813 57.692 58.113 56.175 
10 42.873 62.494 65.873 66.183 63.842 
11 49.564 69.742 70.564 71.932 69.132 
12 55.472 76.543 79.472 81.032 79.533 
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Figure 6.19: In-vitro drug release from Nystatin micropsonge gel formulation 
 
CONCLUSION 
Microsponges containing Nystatin were prepared by quasi 
emulsion solvent diffusion method using ethyl cellulose and 
PVA. By considering the solubility study of the drug, polymer 
and the rate of diffusion of the solvent used.  The internal 
phase suitable for the preparation of microsponges to be 
dichloromethane and the external phase was found to be 
water. Mixture of Ethyl cellulose and drug in 
dichloromethane served as internal phase &Solution of PVA 
in water served as external phase. DSC studies of pure drug 
and excipients and their mixtures show that there is no 
interaction between drug and excipients. 
 All the microsponge formulations were subjected to drug 
content estimation, the low SD values indicates drug content 
was uniform and reproducible in all the formulations. All the 
microsponge formulations were subjected for loading 
efficiency and the results were found to be reproducible.The 
IR spectral analysis suggested that there was no interaction 
between the drug and formulation additive. The drug exists 
in original form and available for the biological action.From 
dissolution studies it was found out that microsponge batch 
no. F3 gave maximum drug release. 
The comparative study of Nystatin gel and Nystatin 
microsponge loaded gel was performed. The release profile 
of both the formulation was studied using franz diffusion 
cell, From the results it can be concluded that microsponge 
loaded gel shows good release of drug as compare to 
nystatin gel. 
REFERENCES 
1. Nokhodchi A, Jelvehgari M, Siahi MR, Mozafari MR. Factors 
affecting the morphology of benzoyl peroxide microsponges. 
Micron 2007; 38:834–840. 
2. Orlu M, Cevher E, Araman A. Design and evaluation of colon 
specific drug delivery system containing flurbiprofen 
microsponges. Int. J. Pharm. 2006; 318:103-117. 
3. Emanuele AD, Dinarvand R. Preparation, characterization and 
drug release From thermo responsive microspheres, Int. J. 
Pharm.; 1995, 237-242. 
4. Jones DS, Pearce KJ. Investigation of the effects of some 
process variables on, microencapsulation of propranolol HCl 
by solvent evaporation method. Int. J.Pharm. 1995; 118:99-
205. 
5. Vyas SP, Khar RK, Targeted and Controlled Drug Delivery-
Novel Carrier System: New Delhi: CBS Publication, 2002, p. 
453-95. 
6. Nacht V. Katz M. The microsponge: a novel topical 
programmable delivery system, in: D.W. Osborne, A.H. 
Amman (Eds.), Topical Drug Delivery Formulations, Marcel 
Dekker: New York, Basel; 1990:299-325. 
7. Patel G, Patel JK. Use of a Microsponge in Drug Delivery 
Systems. Available 
from:URL:http:www.pharmpro.com/ShowPR.aspx?PUBCODE
=021&ACCT=0000100&ISSUE=0602&RELTYPE=PR&ORIGRE
LTYPE=ATO&PROCODE=0 
000&PRODLETT=B&CommonCount=0. 
8. Garg R., Kumar S, Gupta G. Topical Gel: A Review,   
http://www.pharmainfo.net. 2008,63. 
9.  Sharma S, Goswami J, Gupta G, Mustafa A, Topical Drug 
Delivery Systems: A Review,  http://www.pharmainfo.net.  
2008.6 (5).  
10. Banker, Rhodes P. Modern Pharmaceutics. edited by Gilberts 
Banker, Mercel Dekker, New York, 4thEdn 2000,189-191. 
11. Howard C, Nicholas G., Ointments, creams and gels. In: 
Pharmaceutical dosage forms and drug delivery system. in 
editors loyd V. Allen , Nicholas,G.popovich, Howard C Ansel 
7thEdn, New Delhi ,2000, 2.44-250 
12. Waugh A, Grant A, Ross and Wilson. Anatomy & Physiology in 
Health & Illness. Elsevier Science Ltd , 9thEdn .  New York, 2003 
361-372. 
13. Jain A, Gautam S, Gupta Y, Khambete H,  Jain S. Development 
and characterization of ketoconazole emulgel for topical drug 
delivery. Pelagia Research Library. 2010; 1:221-231. 
14. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice 
Of Industrial Pharmacy..Varghese Publishing House, 3rd Ed. 
Bombay; 1987:293-345 
15. Laithy HM. and El shaboury KMF. Thedevelopment of 
CutinaLipogels and gelmicroemulsion for topical 
administration offluconazole. AAPS PharmSciTech. 2003; 
3:25. 
16. Eccleston GM. Emulsions. In: Swarbrick J, Boylan JC, 
eds.Encyclopedia of Pharmaceutical Technology,: Marcel 
Dekker Inc; New York 1992:137-188. 
17. Clyde MO, Cathy MK. Gels and Jellies., In Swarbrick J, Boylan 
JC, editors. Encyclopedia of Pharmaceutical Technology. 
Marcel Dekker. 3rdEdn. New York. 1875-1889. 2007 
18. Mohamed M I, Optimization of Chlorphen esinEmulgel 
Formulation. AAPS PharmSciTech. 2004, 6:26. 
19. Vijaya Bhanu P, Shanmugam V,Lakshmi PK,  Development And 
Optimization Of Novel Diclofenac EmulgelFor Topical Drug 
Delivery International Journal Of Comprehensive Pharmacy 
2011, 9(10). 
0
10
20
30
40
50
60
70
80
90
1 2 3 4 5 6 7 8 9 10 11 12 13
Nystatin gel
Microsponge loaded batches F1
Microsponge loaded batches F2
Microsponge loaded batches F3
Microsponge loaded batches F4
Bansode et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):451-461 
ISSN: 2250-1177                                                                                  [461]                                                                                 CODEN (USA): JDDTAO 
20. Kappor D., Patel M., Vyas R., Lad C., & Tyagi B. A review on 
microsponge drug delivery system. Journal of Drug Delivery 
and Therapeutics, 2014; 4(5):29-35.  
21. Khullar R , Kumar D, Seth N, Saini S. Formulation and 
evaluation of mefenamic acid emulgel for topical delivery. 
Saudi Pharmaceutical Journal. 2012; 20:63-67 
22. Jelvehgari M, Siahi-Shadbad M.R., Azarmi S., Gary P.Martin, Ali 
Nokhodchi. The microsponge delivery system of benzoyl 
peroxide preparation, characterization and release studies. 
International Journal of Pharmaceutics, 2006; 308:124–132. 
23. Orlu M, Cevher E, Araman A. Design and evaluation of colon 
specific drug delivery system containing flurbiprofen 
microsponges. Int. J. Pharm. 2006; 318: 103-117. 
24. Jelvehgari M, Siahi-Shadbad M.R., Azarmi S., Gary P. Martin, Ali 
Nokhodchi. The microsponge delivery system of benzoyl 
peroxide preparation, characterization and release studies. 
International Journal of Pharmaceutics, 2007; 308:124–132. 
25. Nacht V. Katz M. The microsponge: a novel topical 
programmable delivery system, in: D.W. Osborne, A.H. 
Amman (Eds.), Topical Drug Delivery Formulations, Marcel 
Dekker: New York, Basel; 1990: 299-325. 
26. Madan M, Bajaj A, Amrutiya N. Formulation and in vitro 
evaluation of topical emulgel containing combination of a 
local anaesthetic and an anti-inflammatory drug. Indian 
Journal of Pharmaceutical Education and Research. 2009; 
43:351. 
27. Mehta M, Panchal A, Shah VH, Upadhyay Uprepared and 
evaluated controlled release microsponge gel for topical 
delivery of Clotrimazole International Journal of 
Biopharmaceutics. 2013; 4(3):225-230. 
28. Quiñones D., Ms; Evone S. Ghaly., Formulation and 
characterization of Nystatin gel. PRHSJ 2008; 27(1):61-67. 
29. Kaur R., Kaur S.  Role of Polymers in Drug Delivery. Journal of 
Drug Delivery and Therapeutics, 2014; 4(3):32-36.  
30. Chandramouli Y., Shaik F., RajalakshmiR.,Yasmeen R.B. 
Preparation and evaluation of  microsponge loaded controlled 
release topical gel of acyclovir sodium. International Journal 
of Biopharmaceutics. 2012; 3(2): 96-102. 
31. Raymond C., Paul J., Paul J. W. Handbook of Pharmaceutical 
Excipients.5thedition.Published by Pharm. press. New York; 
2006.P.89, 90,159,160,317-322,622-624. 
32. Indian Pharmacopoeia: Controller of Publications, Govt. of 
India, Ministry of 
33. Health & Family Welfare, New Delhi, vol.1, 1996:7: 511-513 
34. Indian Pharmacopoeia: Government of India, Ministry of 
Health & Family welfare, New Delhi, Vol. 1, 2007: 134 
35. Jagdale S. C. Jadhav V. N, Chabukswar A. N, Kuchekar B. S, 
Solubility enhancement, physicochemical characterization 
and formulation of fast-dissolving tablet of Nifedipine-
Betacyclodextrin complexes, Brazilian Journal of 
Pharmaceutical Sciences 2012: vol. 48, jan./mar:131-145. 
36. Patil A, Madgulkar A.Surface Morphology and Drug Release 
Studies on    Repaglinide Controlled Release Pellets Prepared 
by Solution Layering Method with Blend of PEG - HPMC - EC 
Polymers .Pharma Tutor article.2010. 
37. Jaiswal, P., Kesharwani S., Kesharwani R., Patel D. Ethosome:  
A New Technology used as Topical & Transdermal Delivery 
System. Journal of Drug Delivery and Therapeutics, 2016; 
6(3):7-17. 
38. Rastogi V., Shukla S., Singh R., Lal N., & Yadav P. Microspheres: 
A Promising Drug Carrier. Journal of Drug Delivery and 
Therapeutics, 2016; 6(3):18-26.  
39. Bhatt P, Gananaranjan G. Emulgel :A novel formulation 
approach for topical delivery of Hydrophobic drugs.IRJP,2013 
4(2). 
40. Panwar AS, Upadhyay N, Emulgel: A Review asian Journal Of 
Pharmacy And Life Science July-Sept, 2011; 1(3).  
 
 
 
 
